CD40 Ligand, Soluble, Recombinant, Human (CD40L, CD40-L, hCD40L, CD40LG, CD154, gp39, HIGM1, IGM, IMD3, T-BAM, T-cell Antigen Gp39, TNF-related Activation Protein, TRAP, Tumor Necrosis Factor Ligand Superfamily Member 5, TNFSF5)

Source:\nRecombinant corresponding to 149aa of human soluble CD40(CD154) Ligand/TRAP expressed in E.coli is a non-glycosylated, polypeptide chain.\n\nMolecular Weight:\n~16.3kD\n\nBiological Activity:\nThe ED50 as determined by the dose-dependent stimulation of IL-12 & IL-8 induction by PMB (Peripheral Mononuclear) cells was found to be 5-10nug/ml.\n\nDimers and Aggregates:\n(same/less than)1% (SDS-PAGE)\n\nProtein Content:\nProtein quantitation was carried out by two independent methods:1. UV spectroscopy at 280nm using the absorbency value of 1.1 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENEcomputer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a standard solution of soluble CD40L as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C2392-31H

Size

10ug

Form

Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to (same/more than)0.1mg/ml.

Purity

~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: (same/less than)0.1ng/ug (IEU/ug)

References

1. Targeting LFA-1 and CD154 Suppresses the In Vivo Activation and Development of Cytolytic (CD4-Independent) CD8+ T Cells. J Immunol 2005 Dec 15;175(12):7855-7866. 2. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-{gamma}- and CD40L-mediated costimulation. J Leukoc Biol 2005 Dec 5; 3. The expression of CD40-CD40L and activities of matrix metalloproteinases in atherosclerotic rats.\nMol Cell Biochem 2006 Jan;282(1-2):141-6. 4. Differential responses of human B-lymphocyte subpopulations to graded levels of CD40-CD154 interaction. Immunology 2005 Dec;116(4):454-63. 5. Evidence for the requirement for CD40-CD154 interactions in resistance to infections with attenuated Salmonella. J Endotoxin Res 2005;11(6):395-9. 6. Preferential Th2 polarization by OCH is supported by incompetent NKT cell induction of CD40L and following production of inflammatory cytokines by bystander cells in vivo. Int Immunol 2005 Dec;17(12):1619-29.